Byondis
Clinical-stage biopharmaceutical company focused on discovery, development and in-house manufacture of targeted oncology medicines, with an emphasis on next-generation antibody-drug conjugates (ADCs). The organization integrates discovery, CMC/CMC strategy, GLP/GMP development and regulatory filing capabilities and pursues partnerships and licensing for platform and program development.
Industries
Nr. of Employees
large (251-1000)
Patents
Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
US-12178881-B2
View DetailsSite-specific conjugation of linker drugs to antibodies and resulting ADCs
US-12180552-B2
View Details
Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
US-12178881-B2
View DetailsSite-specific conjugation of linker drugs to antibodies and resulting ADCs
US-12180552-B2
View DetailsProducts
SIRPα-directed monoclonal antibody clinical program
Clinical-stage monoclonal antibody program targeting the SIRPα innate immune checkpoint aimed at potentiating antibody-dependent tumor cell clearance.
c-MET-targeting ADC clinical program
ADC program targeting c-MET with a cleavable DNA-alkylating payload showing preclinical potency and bystander killing in low-target-expression models.
CD123-targeting ADC preclinical/clinical program
ADC program targeting CD123 demonstrated preclinical activity and combination potential with other AML therapies.
HER2-directed duocarmazine-based ADC clinical programs
Programs using a duocarmazine-type cleavable linker-drug on HER2-directed antibodies evaluated in late-stage clinical studies and regulatory interactions.
BYON4228
BYON4228 is a mAb from our next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors’ ability to escape from recognition and destruction by the immune system.
BYON4413
BYON4413 is an ADC directed against the molecular target CD123 (interleukin-3 receptor alpha chain), which is expressed on many hemato-oncological malignancies.
SIRPα-directed monoclonal antibody clinical program
Clinical-stage monoclonal antibody program targeting the SIRPα innate immune checkpoint aimed at potentiating antibody-dependent tumor cell clearance.
c-MET-targeting ADC clinical program
ADC program targeting c-MET with a cleavable DNA-alkylating payload showing preclinical potency and bystander killing in low-target-expression models.
CD123-targeting ADC preclinical/clinical program
ADC program targeting CD123 demonstrated preclinical activity and combination potential with other AML therapies.
HER2-directed duocarmazine-based ADC clinical programs
Programs using a duocarmazine-type cleavable linker-drug on HER2-directed antibodies evaluated in late-stage clinical studies and regulatory interactions.
BYON4228
BYON4228 is a mAb from our next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors’ ability to escape from recognition and destruction by the immune system.
BYON4413
BYON4413 is an ADC directed against the molecular target CD123 (interleukin-3 receptor alpha chain), which is expressed on many hemato-oncological malignancies.
Services
End-to-end discovery, preclinical and clinical development combined with in-house GMP manufacturing and clinical batch production.
Modular partnering options including co-development, licensing and access to individual platform technologies (payloads, masking, conjugation).
End-to-end discovery, preclinical and clinical development combined with in-house GMP manufacturing and clinical batch production.
Modular partnering options including co-development, licensing and access to individual platform technologies (payloads, masking, conjugation).
Expertise Areas
- Antibody-drug conjugate development
- Payload and linker chemistry
- Antibody conjugation and engineering
- Preclinical pharmacology and translational models
Key Technologies
- Cleavable DNA-alkylating linker-drug chemistry
- Partial native disulfide conjugation
- Site-specific cysteine conjugation
- Dual-linker/dual-payload conjugation
News & Updates
Appointment of Christoph Korpus as Chief Business Officer (CBO).
First patient dosed in a Phase 1 clinical trial of a SIRPα-directed monoclonal antibody in advanced/metastatic solid tumors.
Appointment of a new Chief Executive Officer.
U.S. Food and Drug Administration issued a complete response letter related to a duocarmazine-based HER2-directed ADC.
Official opening of company R&D and manufacturing campus.
Preclinical data on a pan-allelic antagonistic SIRPα antibody published in a peer-reviewed immuno-oncology journal.
Appointment of Christoph Korpus as Chief Business Officer (CBO).
First patient dosed in a Phase 1 clinical trial of a SIRPα-directed monoclonal antibody in advanced/metastatic solid tumors.
Appointment of a new Chief Executive Officer.
U.S. Food and Drug Administration issued a complete response letter related to a duocarmazine-based HER2-directed ADC.
Official opening of company R&D and manufacturing campus.
Preclinical data on a pan-allelic antagonistic SIRPα antibody published in a peer-reviewed immuno-oncology journal.